Nasdaq

OncoCyte Announces Successful Completion of CLIA Validation Study of DetermaDx™

IRVINE, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel tests for the early diagnosis and management of lung cancer, today announced the ...
Nasdaq

Oncocyte Announces the Launch of CLIA-validated DetermaIO™, a Novel Gene Expression-Based Immune Therapy Response Predictor, for Research Use by Biopharmaceutical Companies ...

Company completes CLIA Validation of DetermaIO™, previously the Insight Genetics IM Score Test, establishing the test as a reliable and robust assay for identifying patients likely to respond to ...
Business Wire

Precision Pathology Services and bioAffinity Technologies Announce Initiation of CLIA Validation for Non-Invasive Early Lung Cancer Test

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services, a CAP/CLIA-certified anatomic and ...
Benzinga.com

Mammogen Achieves CLIA Validation of gen-TRU-breast™ Assay

After two decades effecting change in commercial diagnostics, this achievement is the brightest spot of my career, with a profound culmination of scientific, clinical, and social impact," —Elizabeth ...
Longview News-Journal

1Cell.Ai Completes CLIA Validation Study of OncoIncytes 1080-Gene NGS Panel

FOSTER CITY, Calif., May 28, 2025 /PRNewswire/ -- 1Cell.Ai, a precision oncology company developing advanced cell and molecular profiling platforms, announced the successful completion of a CLIA-grade ...